跳至主要内容
临床试验/NCT01975246
NCT01975246已完成3 期

An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg

Boehringer Ingelheim30 个研究点 分布在 1 个国家目标入组 309 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
309
试验地点
30
主要终点
Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.

研究概览

简要总结

This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/A5 mg.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
20 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Telmisartan+amlodipine+HCTZ

Experimental

telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet

干预措施: Telmisartan + amlodipine (Drug)

Telmisartan+amlodipine+HCTZ

Experimental

telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet

干预措施: hydrochlorothiazide (Drug)

Telmisartan+amlodipine

Active Comparator

telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet

干预措施: Telmisartan + amlodipine (Drug)

Telmisartan+amlodipine

Active Comparator

telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet

干预措施: Placebo (Drug)

结局指标

主要结局

Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.

时间窗: baseline and week 8

Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.

次要结局

  • Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.(baseline and week 8)
  • The Proportion of Patients With DBP<90 mmHg and SBP<140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period(baseline and week 8)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (30)

Loading locations...

相似试验